Blood and Tissue Biomarkers in Prostate Cancer: State of the Art
Blood and Tissue Biomarkers in Prostate Cancer: State of the Art
复制标题
DOI：
10.1016/j.ucl.2009.11.006
复制
发表时间：
2010-02-01
影响因子：
2.4
通讯作者：
Loda, Massimo
中科院分区：
文献类型：
--
作者：
Fiorentino, Michelangelo;Capizzi, Elisa;Loda, Massimo
前列腺癌（PCa）的患病率很高，并且随着年龄的增长而增加。 PCa 是美国男性中最常见的皮肤癌。前列腺特异性抗原 (PSA) 筛查影响了 PCa 的检测，并直接导致诊断阶段的急剧下降。在缺乏更准确和可靠的组织或血液生物标志物的情况下，诊断时的格里森评分和分期仍然是预测预后的主要依据。尽管进行了大量的研究工作，但迄今为止，很少有 PCa 生物标志物被引入临床实践。甚至 PSA 筛查最近也受到质疑。对前列腺癌研究中所有组织和血清生物标志物的彻底分析无法轻易合成，并且超出了本文的范围。因此，作者在此重点关注最近报道的 PCa 组织和循环生物标志物，其在临床实践中的应用要么是当前的，要么是预期在不久的将来。
The prevalence of prostate cancer (PCa) is high and increases with age. PCa is the most common cutaneous cancer in American men. Prostate-specific antigen (PSA) screening has impacted the detection of PCa and is directly responsible for a dramatic decrease in stage at diagnosis. Gleason score and stage at the time of diagnosis remain the mainstay to predict prognosis, in the absence of more accurate and reliable tissue or blood biomarkers. Despite extensive research efforts, very few biomarkers of PCa have been introduced to date in clinical practice. Even screening with PSA has recently been questioned. A thorough analysis of all tissue and serum biomarkers in prostate cancer research cannot be easily synthesized, and goes beyond the scope of the present article. Therefore the authors focus here on the most recently reported tissue and circulating biomarkers for PCa whose application in clinical practice is either current or expected in the near future.